Clinical trial
A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
NCT00150579 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
- Lead sponsor
- Shire
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 27, 2005
- Completion date
- June 14, 2005
- Enrollment
- 240
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.